Pharmacokinetic Impacts of Hyperlipidemia in Rodent Models

Hyperlipidemia in rodents, most commonly induced by intraperitoneal administration of poloxamer 407 or dietary manipulation, profoundly alters the pharmacokinetic profile of diverse compounds. Elevations in triglycerides and cholesterol-rich lipoproteins can modify drug absorption by influencing intestinal solubility and epithelial transport. Once in the circulation, increased binding of lipophilic agents to expanded lipoprotein pools often reduces the fraction of free drug, leading to an apparent decrease in volume of distribution. Hepatic metabolism may be attenuated through downregulation of key cytochrome P450 isoforms or altered enzyme activity in S9 fractions, prolonging systemic exposure. First-pass elimination is similarly affected, with reduced intestinal and hepatic clearance contributing to higher oral bioavailability for susceptible substrates. Renal excretion can be influenced indirectly by competition for protein-binding sites and altered glomerular filtration of unbound molecules. Collectively, these changes challenge dose selection and safety margins in preclinical studies, highlighting the need for careful pharmacokinetic characterisation in hyperlipidaemic contexts. Insight into these alterations supports improved prediction of drug behaviour in patients with dyslipidaemia and informs the design of lipid-modulating co-therapies.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Pharmacokinetic Impacts of Hyperlipidemia in Rodent Models publication trend

The graph below shows the total number of articles in pharmacokinetic impacts of hyperlipidemia in rodent models across all publications each year (not limited to Nature Index journals).

Technical terms

Poloxamer 407: A non-ionic surfactant used to induce reversible hyperlipidaemia in rodents by inhibiting lipoprotein lipase activity.

Area under the concentration–time curve (AUC): The integral of the drug concentration in plasma over time, reflecting total systemic exposure.

Clearance (CL): The volume of plasma from which a drug is completely removed per unit time, encompassing hepatic and renal elimination.

Volume of distribution (Vd): A theoretical volume that relates the amount of drug in the body to the concentration measured in plasma, indicating distribution into tissues and blood components.

Unbound fraction (fu): The proportion of total drug in plasma not bound to proteins or lipoproteins, representing the pharmacologically active pool.

First-pass metabolism: The initial biotransformation of an orally administered drug by intestinal and hepatic enzymes before it reaches systemic circulation.

References

1. The single dose poloxamer 407 model of hyperlipidemia; systemic effects on lipids assessed using pharmacokinetic methods, and its effects on adipokines.. Journal of Pharmacy & Pharmaceutical Sciences (2013).
2. Effects of experimental hyperlipidemia on the pharmacokinetics of tadalafil in rats.. Journal of Pharmacy & Pharmaceutical Sciences (2012).
3. The effect of increased lipoproteins levels on the disposition of vincristine in rat. Lipids in Health and Disease (2016).